Background: Recently, a small population of cancer stem cells in adult and pediatric brain tumors has been identified. Some evidence has suggested that CD133 is a marker for a subset of leukemia and glioblastoma cancer stem cells. Especially, CD133 positive cells isolated from human glioblastoma may initiate tumors and represent novel targets for therapeutics. The gene expression and the drug resistance property of CD133 positive cancer stem cells, however, are still unknown.
Results: In this study, by FACS analysis we determined the percentage of CD133 positive cells in three primary cultured cell lines established from glioblastoma patients 10.2%, 69.7% and 27.5%, respectively. We also determined the average mRNA levels of markers associated with neural precursors. For example, CD90, CD44, CXCR4, Nestin, Msi1 and MELK mRNA on CD133 positive cells increased to 15.6, 5.7, 337.8, 21.4, 84 and 1351 times, respectively, compared to autologous CD133 negative cells derived from cell line No. 66. Additionally, CD133 positive cells express higher levels of BCRP1 and MGMT mRNA, as well as higher mRNA levels of genes that inhibit apoptosis. Furthermore, CD133 positive cells were significantly resistant to chemotherapeutic agents including temozolomide, carboplatin, paclitaxel (Taxol) and etoposide (VP16) compared to autologous CD133 negative cells. Finally, CD133 expression was significantly higher in recurrent GBM tissue obtained from five patients as compared to their respective newly diagnosed tumors.
Conclusion: Our study for the first time provided evidence that CD133 positive cancer stem cells display strong capability on tumor's resistance to chemotherapy. This resistance is probably contributed by the CD133 positive cell with higher expression of on BCRP1 and MGMT, as well as the anti-apoptosis protein and inhibitors of apoptosis protein families. Future treatment should target this small population of CD133 positive cancer stem cells in tumors to improve the survival of brain tumor patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1697823 | PMC |
| http://dx.doi.org/10.1186/1476-4598-5-67 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology.
Bioact Mater
March 2025
School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong, 264005, China.
Despite significant advances in targeted therapies and immunotherapies, non-small cell lung cancer (NSCLC) continues to present a global health challenge, with a modest five-year survival rate of 28 %, largely due to the emergence of treatment-resistant and metastatic tumors. In response, we synthesized a novel bioactive compound, ethyl 6-chlorocoumarin-3-carboxylyl L-theanine (TClC), which significantly inhibited NSCLC growth, epithelial mesenchymal transition (EMT), migration, and invasion and tumor growth and metastasis without inducing toxicity. TClC disrupts autocrine loops that promote tumor progression, particularly in stem-like CD133-positive NSCLC (CD133+ LC) cells, which are pivotal in tumor metastasis.
View Article and Find Full Text PDFBackground: CD133 is regarded as a marker and target for cancer stem cells (CSCs) in various types of tumors, including hepatocellular carcinoma (HCC). The expressions of CD133 and programmed cell death ligand 1 (PD-L1) in CSCs exhibit a positive feedback regulatory effect. This effect promotes CSC proliferation and immune escape, ultimately leading to tumor progression and poor prognosis.
View Article and Find Full Text PDFRegulatory factor X-5/SCL/TAL1 interruption site axis promotes aerobic glycolysis and hepatocellular carcinoma cell stemness.
Kaohsiung J Med Sci
January 2025
Department of General Surgery Ward One, Anyang Tumor Hospital, Anyang, Henan, China.
The incidence and development of various tumors, such as hepatocellular carcinoma (HCC), are linked to tumor stem cells. Although research has revealed how important SCL/TAL1 interruption site (STIL) is in many human tumors, the impact of STIL on HCC stem cells is poorly understood. This study aimed to examine the regulatory mechanisms and the function of STIL in the stemness of HCC tumor cells.
View Article and Find Full Text PDFAn Injectable Solution for Preservation of Hematopoietic Stem and Progenitors Cells in Hypothermic Condition.
Stem Cell Rev Rep
December 2024
Etablissement Français du Sang Nouvelle Aquitaine, CS21010, Bordeaux-Cedex, 3035, France.
To ensure the preservation of functional hematopoietic stem cells (HSC) and committed progenitor cells (HPC) at + 4 °C in ex vivo expanded cord blood cell products during worldwide transportation and subsequent infusion-without the need for washing and cell concentration-we developed a conservation medium called Stabilizer of Expanded Cells (SEC), composed exclusively of injectable pharmacological products. The in vivo engraftment assay in immunodeficient mice was used to detect primitive HSCs before and after preservation at + 4 °C. In some experiments, a complex phenotype based on CD34, CD38, and CD133 expression was utilized for this purpose.
View Article and Find Full Text PDFStabilization of SQLE mRNA by WTAP/FTO/IGF2BP3-dependent manner in HGSOC: implications for metabolism, stemness, and progression.
Cell Death Dis
December 2024
Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China.
Article Synopsis
- The study highlights the role of squalene epoxidase (SQLE) in the progression and recurrence of high-grade serous ovarian carcinoma (HGSOC), showing its significant upregulation in cancer samples and association with poor patient outcomes.
- SQLE promotes cancer cell growth by driving proliferation and inhibiting apoptosis, while also enhancing stem-like properties in cancer cells, making it a key factor in maintaining HGSOC stemness.
- Additionally, the research indicates that SQLE mRNA stability is influenced by specific modifications and binding proteins, suggesting that targeting SQLE could be a promising strategy for improving HGSOC prognosis and treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!